"These trials suggest that olanzapine is a viable option and an invaluable addition to the pharmacological armamentarium in the treatment of bipolar I disorder. However, this can often be mitigated by safety and tolerability concerns with this agent including weight gain and metabolic syndrome that warrants clinician vigilance and discernment that is imperative in today’s clinical practice. 1.
...
"Substantial advances in the recent years have fostered an expansion in the pharmacological treatment options for bipolar disorder, but optimal management of this devastating illness continues to remain an elusive goal. 1.
"The beneficial effects of atypical antipsychotics are often mitigated by an increased risk of metabolic abnormalities such as dyslipidemia, hyperglycemia, and diabetes mellitus in a population that is already at a heightened risk for metabolic syndrome and cardiovascular morbidity and mortality.
"Several agents used in acute and prophylactic mania treatment including lithium, valproate, olanzapine, quetiapine, and risperidone can cause problematic weight gain, which often can set the stage for non-adherence. Treatment non-adherence is a major concern in bipolar disorder with nearly half of individuals being non-adherent to psychotropic medication they are prescribed. Prudent practice demands a good risk benefit analysis in choosing an agent that is efficacious, safe and well tolerated when making clinical decisions." 1.
More here:
1. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2656294/
No comments:
Post a Comment